Daratumumab is indicated in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||02/06/2020|
|Rapid review completed||17/07/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of daratumumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||04/08/2020|
|Pre-submission consultation with Applicant||21/09/2020|
|Full HTA submission received from Applicant||12/03/2021|
|Preliminary review sent to Applicant||19/07/2021|
|NCPE assessment re-commenced||19/08/2021|
|Factual accuracy check sent to Applicant||04/10/2021|
|NCPE assessment re-commenced||11/10/2021|
|NCPE assessment completed||16/11/2021|
|NCPE assessment outcome||The NCPE recommend that daratumumab (Darzalex®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.